Mammary Cell News 10.39 October 4, 2018 | |
| |
TOP STORYProgramming Niche Accessibility and In Vitro Stemness with Intercellular DNA Reactions An intercellular DNA-reaction-programmed expansion of stem cells with pairing niches strategy was developed for 3D culture of mammary stem cells (MaSCs). Boolean logic operations were implemented to confer DNA-programmed mechanical signaling and genetically engineered morphogen signaling by niche cells, resulting in sustained expansion of MaSCs in vitro. [Adv Mater] Abstract | |
| |
PUBLICATIONS(Ranked by impact factor of the journal)Scientists report that genetic depletion or small molecule inhibition of KDM4B histone demethylase activated the unfolded protein response pathway and resulted in preferential apoptosis in PTEN-deficient triple-negative breast cancers. [J Exp Med] Abstract | Graphical Abstract Researchers observed that X-linked inhibitor of apoptosis protein (XIAP) interacted with p62 and also that XIAP depletion resulted in increased expression of p62. XIAP functioned as an ubiquitination E3 ligase towards p62 and suppressed p62 expression through ubiquitin-proteasomal degradation. [Oncogene] Abstract In vitro, Zt/g4-drug monomethyl auristatin E conjugate (Zt/g4-MMAE) rapidly induced RON internalization, resulted in cell cycle arrest followed by massive cell death. Zt/g4-MMAE also effectively killed triple-negative breast cancer (TNBC) stem-like cells with RON+/CD44+/CD24– phenotypes and RON-negative TNBC cells through the bystander effect. [Mol Cancer Ther] Abstract Breast Cancer Survival Predicted by TP53 Mutation Status Differs Markedly Depending on Treatment Addition of hormone therapy to chemotherapy improved survival notably in patients with TP53 wild-type tumors, but not mutant, suggesting hormone therapy could eradicate arrested/senescent cells. [Breast Cancer Res] Full Article miR-449a Suppresses Tamoxifen Resistance in Human Breast Cancer Cells by Targeting ADAM22 miR-449a levels were downregulated significantly in tamoxifen-resistant breast cancer cells when compared with their parental cells, as well as in clinical breast cancer serum samples. Overexpression of miR-449a re-sensitized the tamoxifen-resistant breast cancer cells, while inhibition of miR-449a conferred tamoxifen resistance in parental cells. [Cell Physiol Biochem] Full Article c-MYC Drives Breast Cancer Metastasis to the Brain, but Promotes Synthetic Lethality with TRAIL Human breast cancer cells and their brain-metastatic derivatives (BrMs) were used to investigate synthetic lethal interactions in BrMs. c-MYC enhanced brain metastasis by facilitating the following processes within the brain microenvironment: invasive growth of BrMs, macrophage infiltration, and GAP-junction formation between BrMs and astrocytes by up-regulating connexin 43. [Mol Cancer Res] Abstract Chemotaxis Model for Breast Cancer Cells Based on Signal-to-Noise Ratio Investigators demonstrated that even under the same epidermal growth factor (EGF) concentration gradients, breast cancer cells revealed more evident chemotaxis pattern when the absolute EGF concentrations were low. They found that reducing the number of EGF receptors (EGFRs) with addition of EGFR antibody could promote chemotaxis at an EGF gradient of 0 – 1 ng/ml as shown by chemotaxis index. [Biophys J] Abstract Aurantoside C Targets and Induces Apoptosis in Triple Negative Breast Cancer Cells Scientists found that aurantoside C (C828) inhibited the phosphorylation of Akt/mTOR and NF-kB pathways and increased the phosphorylation of p38 MAPK and SAPK/JNK pathways, leading to apoptosis in triple negative breast cancer (TNBC) cells. These effects of C828 were not observed in non-TNBC cells at the concentrations that were cytotoxic to TNBC cells. [Mar Drugs] Full Article Rhomboid family-1 (RHBDF1) mediated G-protein coupled receptor agonist-induced epidermal growth factor receptor phosphorylation by promoting TGFα secretion in various types of breast cancer cells. RHBDF1 not only mediates ADAM17-dependent shedding of TGFα, but was essential in membrane trafficking of pro-TGFα. [EBioMedicine] Abstract Subscribe to one of our other 19 science newsletters such as Prostate Cell News & ESC & iPSC News. | |
| |
REVIEWSFunctional Role of MicroRNAs in the Progression of Breast Ductal Carcinoma In Situ The authors review the miRNAs that have been identified in ductal carcinoma in situ (DCIS) and how they may contribute to the progression to invasive disease. They also touch on the current state of miRNA therapeutic development, including the current challenges, and discuss the key future perspectives for research into miRNA function for the purpose of miRNA therapeutic development against DCIS. [Am J Pathol] Abstract Visit our reviews page to see a complete list of reviews in the mammary cell research field. | |
| |
SCIENCE NEWSSELLAS to Present Data from Phase IIb Trial of NeuVax + Herceptin® SELLAS Life Sciences Group, Inc. announced that data from the Phase IIb trial of nelipepimut-S in combination with trastuzumab for the treatment of women with triple-negative breast cancer will be presented. [Press release from SELLAS Life Sciences Group, Inc. discussing research presented at the 2018 Society for Immunotherapy of Cancer (SITC) Annual Meeting, Washington, D.C] Press Release | |
| |
INDUSTRY NEWSTransThera Biosciences Granted IND Approval from FDA to Soon Start Clinical Trials Targeting TNBC TransThera Biosciences Co. Ltd, announced that the company received FDA IND application approval for TT-00420, a novel small molecule investigational drug targeting triple-negative breast cancer (TNBC). [TransThera Biosciences Co. Ltd (PR Newswire Association LLC.)] Press Release Puma Biotechnology, Inc. has been advised that its licensing partner CANbridge Pharmaceutical Inc received confirmation that China’s National Medical Products Administration has accepted its New Drug Application for NERLYNX® for the extended adjuvant treatment of adult patients with early stage HER2-positive breast cancer, following adjuvant trastuzumab based-therapy. [Puma Biotechnology, Inc.] Press Release Researcher Blocks Protein That Defeats Powerful Tumor Suppressor in Breast Cancer Sanjay Awasthi, M.D., a professor in the TTUHSC Department of Internal Medicine and an oncologist, received a Department of Defense $1,147,500 grant for his research, “Prevention of Breast Cancer by Haploinsufficiency of RALBP1.” [Texas Tech University Health Sciences Center (EurekAlert!)] Press Release | |
| |
POLICY NEWSUniversity Tenure Decisions Still Gloss over Scientists’ Public Outreach Universities often tout their commitment to public outreach. But a new study of the internal guidelines for faculty tenure and promotion suggests that institutions don’t always put much value on public engagement. [Nature News] Editorial Women Fare Well in This Year’s Crop of NIH High-Risk Awards The high-risk, high-reward program selects most investigators based on their track record and ideas, rather than a specific research project. After the first winners of the Pioneer Awards in 2004 were all male, women did better in future years, roughly matching the female fraction of the applicant pool. But last year, only one of 12 awardees was a woman. [ScienceInsider] Editorial Brazil’s Presidential Election Could Savage Its Science A populist surge from a right-wing presidential candidate in Brazil that is threatening to upend the country’s politics could have huge impacts on research budgets and environmental policies. [Nature News] Editorial
| |
EVENTSNEW 16th St. Gallen International Breast Cancer Conference Visit our events page to see a complete list of events in the community.
| |
JOB OPPORTUNITIESNEW Postdoctoral Research Fellow – Mammary Stem Cell Biology (University of Southampton) Team Leader – ER Positive Breast Cancer (Institute of Cancer Research) Assistant/Associate/Progessor – Department of Cancer Biology (University of Cincinnati) Scientific Coordinator (Helmholtz Zentrum Munchen) Postdoctoral Fellow – Immunotherapy of Breast Cancer (Boston University School of Medicine) Postdoctoral Fellow – Stem Cells and Cancer (Albert Einstein College of Medicine) Postdoctoral Position – Cancer Biology (GIGA – Universite de Liege) Cancer Faculty Investigators – Breast Cancer (The University of Alabama) Postdoctoral Fellow/Research Scientist – Cancer Research (Icahn School of Medicine at Mount Sinai) Recruit Top Talent: Reach potential candidates by posting your organization’s career opportunities on the Connexon Creative Job Board at no cost.
| |
Have we missed an important article or publication in Mammary Cell News? Click here to submit! Comments or suggestions? Submit your feedback here. | |
|